In healthcare studies, the analysis of claims data is gaining an increasingly important role. Observational studies should be reported in a manner that promotes internal and external validity assessment, with the exact and standardized description of items. Several international guidelines and checklists for reporting on secondary data are available. The aim of this work was to analyse the applicability of reporting guidelines especially for claims data. The STROSA-2 guidelines recommendations were evaluated by means of a report on a study on triptan medications in Austria. Six items were identified which could be expanded to support complete and transparent report on Austrian claims data. Therefore, we would suggest to add some details in the STROSA-2 guidelines concerning study design, legal foundations, data protection, data flow, descriptive results and risk of bias. The guidelines for reporting on Austrian claims data were successfully compiled with additional items. New guidelines should be further processed and tested with strong recommendations to focus on data limitations and legal aspects.